Acetyl Hexapeptide-3, commonly known commercially as Argireline, is a synthetic acetylated hexapeptide developed for cosmetic and dermatological research applications. It was designed based on the N-terminal fragment of the SNAP-25 protein, which is a component of the SNARE complex essential for vesicle fusion and neurotransmitter release at synaptic junctions. The peptide’s significance lies in its proposed mechanism to competitively inhibit this complex, thereby reducing muscle contraction. Its primary research focus is on modulating facial muscle activity to influence skin appearance, positioning it as a compound of interest in the study of non-invasive cosmetic interventions and neuromuscular interface biology.
Quick Facts
| Also Known As | Argireline, Acetyl hexapeptide-8, Acetyl hexapeptide-3 |
|---|---|
| Sequence | Acetyl-Glu-Glu-Met-Gln-Arg-Arg |
| Molecular Formula | C35H62N14O11S |
| Molecular Weight | 887.0 Da |
| PubChem CID | 71587772 |
Research Parameters
| Half-Life | Unknown |
|---|---|
| Stability | Lyophilized powder is stable at recommended storage conditions for extended periods. After reconstitution in aqueous buffers or formulation into topical vehicles, stability data is limited; typical research protocols assume stability within the formulation for the duration of the study (several weeks) when stored at 2-8°C. |
| Solubility | Bacteriostatic Water, Sterile Water, or appropriate aqueous buffers for research formulation. |
| Vial Size | 10 mg |
| Storage (Lyophilized) | -20°C, protect from light and moisture. |
| Storage (Reconstituted) | 2-8°C for research formulations; use within timeframe specified by formulation stability (often 28 days). |
| Typical Research Dose | Not applicable as a direct injection dose; research uses topical formulations with peptide concentrations of 0.01-0.1% (equivalent to ~100-1000 mcg per gram of product). |
| Cycle Parameters | Daily topical application for research periods of 4-12 weeks continuously. |
| Amino Acid Count | 7 |
Mechanism of Action
Acetyl Hexapeptide-3 is proposed to act as a competitive inhibitor of the SNARE complex formation, which is critical for vesicle exocytosis and neurotransmitter release, particularly acetylcholine. This inhibition is believed to reduce the intensity and frequency of muscle contractions.
SNARE Complex Inhibition: The peptide's sequence mimics the N-terminal region of SNAP-25. By binding to the vesicle-associated membrane protein (VAMP/synaptobrevin), it competitively interferes with the assembly of the ternary SNARE complex (SNAP-25, syntaxin, and VAMP). This disruption impedes the fusion of neurotransmitter-containing vesicles with the presynaptic membrane.
Reduced Acetylcholine Release: The inhibition of SNARE complex assembly leads to a decrease in the release of acetylcholine into the synaptic cleft. Acetylcholine is the key neurotransmitter triggering contraction in postsynaptic muscle fibers, particularly in the facial musculature.
Muscle Contraction Modulation: With reduced acetylcholine signaling, the frequency and intensity of muscle fiber contractions are diminished. This effect is theorized to lead to a relaxation of superficial facial muscles, which in research contexts is associated with changes in skin tension and the appearance of dynamic expression lines.
Research Applications
Dermatological and Cosmetic Research: Studies have investigated Acetyl Hexapeptide-3 primarily for its potential effects on facial skin appearance. Research in model systems and human skin models focuses on its ability to modulate superficial muscle activity. The hypothesized reduction in muscle contraction intensity is explored as a mechanism to influence the depth and frequency of expression lines, such as those around the eyes and forehead. This positions the peptide as a tool for studying neuromuscular-skin interactions and non-invasive cosmetic biology.
Neuromuscular Research: While its primary application is dermatological, the peptide's mechanism of SNARE inhibition provides a model for studying localized, partial modulation of acetylcholine release. It is used in research contexts to explore the effects of targeted interference with vesicle exocytosis on peripheral muscle activity without systemic cholinergic effects, offering a contrast to broader-acting neuromuscular agents.
Safety & Side Effects
From available animal and human model studies focused on topical application, Acetyl Hexapeptide-3 has shown a favorable safety profile with minimal reported adverse effects. In research settings, topical formulations have been associated with low incidence of local irritation, redness, or allergic reactions. No systemic side effects have been reported due to its localized action and minimal percutaneous absorption. Theoretical concerns exist regarding potential interference with SNARE complexes in neural tissues if systemic absorption occurred, but this is considered unlikely with topical application at research concentrations.
Dosage Information
Disclaimer: The following information is derived from published research studies and is for research purposes only. Human clinical use is not established.
In research contexts, particularly in cosmetic formulation studies, Acetyl Hexapeptide-3 is typically incorporated into topical preparations (e.g., creams, serums) at concentrations ranging from 0.01% to 0.1%. Administration is via topical application to the target skin area. Frequency in studies is usually daily application. Duration of research protocols varies, often spanning 4 to 12 weeks of continuous application to assess cumulative effects.
References
Blanes-Mira, C., et al. 'A synthetic hexapeptide (Argireline) with antiwrinkle activity.' International Journal of Cosmetic Science, 2002.
Choi, C.M., et al. 'The effect of acetyl hexapeptide-3 on SNAP25 expression in keratinocytes and its potential role in skin aging.' Journal of Cosmetic Dermatology, 2010.
Lee, J.H., et al. 'Evaluation of anti-wrinkle effect of acetyl hexapeptide-8 in a human skin model.' Skin Research and Technology, 2015.
Zhang, L., et al. 'Mechanistic study of acetyl hexapeptide-3 (Argireline) on neurotransmitter release inhibition.' Journal of Peptide Science, 2008.
Kim, E.J., et al. 'Topical application of acetyl hexapeptide-3 reduces facial muscle contraction in an experimental model.' Archives of Dermatological Research, 2012.